Ionis Pharmaceuticals Overview

  • Status
  • Public

  • Employees
  • 1,402

Employees

  • Stock Symbol
  • IONS

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $29.06
  • (As of Friday Closing)

Ionis Pharmaceuticals General Information

Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Contact Information

Website
www.ionis.com
Formerly Known As
Isis Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States
+1 (760)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States
+1 (760)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ionis Pharmaceuticals Stock Performance

As of 13-Nov-2026, Ionis Pharmaceuticals’s stock price is $29.06. Its current market cap is $4.84B with 167M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.06 $27.31 $27.25 - $86.74 $4.84B 167M 3.79M -$3.33

Ionis Pharmaceuticals Financials Summary

As of 30-Sep-2026, Ionis Pharmaceuticals has a trailing 12-month revenue of $960M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,979,067 12,063,114 4,483,467 6,475,002
Revenue 960,092 943,711 705,138 787,647
EBITDA (444,504) (272,625) (353,721) (230,010)
Net Income (546,539) (381,387) (453,897) (366,286)
Total Assets 2,912,590 3,523,836 3,003,675 2,990,072
Total Debt 1,629,186 2,064,512 1,416,569 1,453,539
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ionis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad cl
Drug Discovery
Carlsbad, CA
1,402 As of 2026

Pasadena, CA
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ionis Pharmaceuticals Competitors (48)

One of Ionis Pharmaceuticals’s 48 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Gilead Formerly VC-backed Foster City, CA
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 48 competitors. Get the full list »

Ionis Pharmaceuticals Patents

Ionis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213260-A1 Methods for modulating lrrk2 Pending 04-Apr-2025
WO-2026193287-A1 Modified oligonucleotides Pending 13-Mar-2025
WO-2026193290-A1 Polypeptides and uses thereof Pending 13-Mar-2025
WO-2026151867-A1 Compounds and methods for modulating hnrnph2 expression Pending 09-Jan-2025
WO-2026128506-A1 Lipid encapsulated nanoparticles Pending 10-Dec-2024 C07D207/12
To view Ionis Pharmaceuticals’s complete patent history, request access »

Ionis Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ionis Pharmaceuticals Investments & Acquisitions (20)

Ionis Pharmaceuticals’s most recent deal was a Early Stage VC with Aro Biotherapeutics for . The deal was made on 23-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aro Biotherapeutics 23-Nov-2021 Early Stage VC Biotechnology
Bicycle Therapeutics 09-Jul-2021 PIPE Drug Discovery
Akcea Therapeutics 12-Oct-2020 Merger/Acquisition Drug Discovery
Empirico 20-Dec-2019 Early Stage VC Biotechnology
Dynacure 10-Nov-2017 Early Stage VC Drug Discovery
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Ionis Pharmaceuticals ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Ionis Pharmaceuticals’s complete esg history, request access »

Ionis Pharmaceuticals Exits (14)

Ionis Pharmaceuticals’s most recent exit was on 09-Jul-2021 from Bicycle Therapeutics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Bicycle Therapeutics 09-Jul-2021 Completed
Dynacure 10-Nov-2017 Completed
YourBio Health 06-Sep-2017 Completed
Suzhou Ribobio Biotechnology 17-Mar-2017 Completed
  • 9 buyers
Dynacure 01-Oct-2016 Accelerator/Incubator Completed
  • 3 buyers
You’re viewing 5 of 14 exits. Get the full list »

Ionis Pharmaceuticals FAQs

  • Where is Ionis Pharmaceuticals headquartered?

    Ionis Pharmaceuticals is headquartered in Carlsbad, CA.

  • What is the size of Ionis Pharmaceuticals?

    Ionis Pharmaceuticals has 1,402 total employees.

  • What industry is Ionis Pharmaceuticals in?

    Ionis Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Ionis Pharmaceuticals a private or public company?

    Ionis Pharmaceuticals is a Public company.

  • What is Ionis Pharmaceuticals’s stock symbol?

    The ticker symbol for Ionis Pharmaceuticals is IONS.

  • What is the current stock price of Ionis Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Ionis Pharmaceuticals is $29.06.

  • What is the current market cap of Ionis Pharmaceuticals?

    The current market capitalization of Ionis Pharmaceuticals is $4.84B.

  • What is Ionis Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Ionis Pharmaceuticals is $960M.

  • Who are Ionis Pharmaceuticals’s competitors?

    Arrowhead Pharmaceuticals, Gilead, Alaunos Therapeutics, Crinetics Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 48 competitors of Ionis Pharmaceuticals.

  • What is Ionis Pharmaceuticals’s annual earnings per share (EPS)?

    Ionis Pharmaceuticals’s EPS for 12 months was -$3.33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process